156 related articles for article (PubMed ID: 19858082)
1. Acute aortic dissection during sorafenib-containing therapy.
Serrano C; Suárez C; Andreu J; Carles J
Ann Oncol; 2010 Jan; 21(1):181-2. PubMed ID: 19858082
[No Abstract] [Full Text] [Related]
2. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
[TBL] [Abstract][Full Text] [Related]
3. Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
Ravaud A; Grossgoupil M
Lancet Oncol; 2010 Apr; 11(4):307-8. PubMed ID: 20359658
[No Abstract] [Full Text] [Related]
4. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Stadler WM
Urologe A; 2004 Sep; 43 Suppl 3():S145-6. PubMed ID: 15164180
[No Abstract] [Full Text] [Related]
6. Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
Staehler M; Haseke N; Roosen A; Stadler T; Bader M; Siebels M; Karl A; Stief CG
Eur J Med Res; 2010; 15(7):287-91. PubMed ID: 20696639
[TBL] [Abstract][Full Text] [Related]
7. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
Ravaud A; Sire M
Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
[No Abstract] [Full Text] [Related]
8. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Kodaira M; Takahashi S; Takeuchi K; Yuasa T; Saotome T; Yonese J; Fukui I; Hatake K
Ann Oncol; 2010 Jul; 21(7):1563-1565. PubMed ID: 20573851
[No Abstract] [Full Text] [Related]
10. Kidney cancer: Does hypothyroidism predict clinical outcome?
Rini B
Nat Rev Urol; 2011 Jan; 8(1):10-1. PubMed ID: 21116300
[No Abstract] [Full Text] [Related]
11. Sorafenib in locally advanced or metastatic breast cancer.
Gradishar WJ
Expert Opin Investig Drugs; 2012 Aug; 21(8):1177-91. PubMed ID: 22616580
[TBL] [Abstract][Full Text] [Related]
12. New therapeutic options for renal cell carcinoma.
Stadler W
Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
[No Abstract] [Full Text] [Related]
13. Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.
Jonkers IJAM; van Buren M
Clin Exp Nephrol; 2009 Aug; 13(4):397-401. PubMed ID: 19381758
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
Williet N; Dubreuil O; Boussaha T; Trouilloud I; Landi B; Housset M; Botti M; Rougier P; Belghiti J; Taieb J
World J Gastroenterol; 2011 May; 17(17):2255-8. PubMed ID: 21633538
[TBL] [Abstract][Full Text] [Related]
15. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
Overkleeft EN; Goldschmeding R; van Reekum F; Voest EE; Verheul HM
Ann Oncol; 2010 Jan; 21(1):184-5. PubMed ID: 19889617
[No Abstract] [Full Text] [Related]
16. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F
Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549
[No Abstract] [Full Text] [Related]
17. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.
El-Khoueiry AB; Ramanathan RK; Yang DY; Zhang W; Shibata S; Wright JJ; Gandara D; Lenz HJ
Invest New Drugs; 2012 Jun; 30(3):1175-83. PubMed ID: 21424698
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Rosen LS; Puzanov I; Friberg G; Chan E; Hwang YC; Deng H; Gilbert J; Mahalingam D; McCaffery I; Michael SA; Mita AC; Mita MM; Mulay M; Shubhakar P; Zhu M; Sarantopoulos J
Clin Cancer Res; 2012 Jun; 18(12):3414-27. PubMed ID: 22510349
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
Larkin JM; Ferguson TR; Pickering LM; Edmonds K; James MG; Thomas K; Banerji U; Berns B; de Boer C; Gore ME
Br J Cancer; 2010 Oct; 103(8):1149-53. PubMed ID: 20842130
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yokosuka AO
Invest New Drugs; 2014 Aug; 32(4):762-8. PubMed ID: 24737402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
